Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Prehospital tranexamic acid (TXA) may hold substantial benefits for trauma patients; however, the data underlying its efficacy and safety is scarce.
Methods: We searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception to July 2023 for all randomized controlled trials (RCTs) investigating prehospital TXA in trauma patients as compared to placebo or standard care without TXA. Data were pooled under a random-effects model using RevMan 5.4 with risk ratio (RR) and mean difference (MD) as the effect measures.
Results: A total of three RCTs were included in this review. Regarding the primary outcomes, prehospital TXA reduced the risk of 1-month mortality (RR 0.82, 95% CI 0.69-0.97) but did not increase survival with a favorable functional outcome at 6 months (RR 1.00, 95% CI 0.93-1.09). Prehospital TXA also reduced the risk of 24-h mortality but did not affect the risk of mortality due to bleeding and traumatic brain injury. There was no significant difference between the TXA and control groups in the incidence of RBC transfusion, and the number of ventilator- and ICU-free days. Prehospital TXA did not increase the risk of adverse events except for a small increase in the incidence of infections.
Conclusion: Prehospital TXA is useful in reducing mortality in trauma patients without a notable increase in the risk of adverse events. However, there was no effect on the 6-month favorable functional status. Further large-scale trials are required to validate the aforementioned findings.
Systematic Review Registration: PROSPERO (CRD42023451759).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623347 | PMC |
| http://dx.doi.org/10.3389/fmed.2023.1284016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autoinjector-based delivery of tranexamic acid provides pharmacokinetic efficacy in a porcine model of uncontrolled hemorrhage.
Injury
August 2025
Institute for Research in Military Medicine (IRMM), Faculty of Medicine, The Hebrew University of Jerusalem and the Israel Defense Forces Medical Corps, Jerusalem, Israel; Department of Military Medicine ("Tzameret"), Faculty of Medicine, The Hebrew University of Jerusalem, and the Israel Defense Fo
Background: Hemorrhage remains the principal cause of death on the battlefield. It is suggested that Tranexamic acid (TXA) can improve survival of severely-bleeding casualties. The intravenous approach is not always available in the pre-hospital setting.
View Article and Find Full Text PDFTranexamic Acid and Systemic Complement Activation in Traumatic Brain Injury Patients.
J Am Coll Surg
August 2025
Division of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska.
Introduction: Traumatic brain injury (TBI) is a leading cause of trauma-related death. A pre-hospital 2-gram bolus of tranexamic acid (TXA) has shown mortality benefit but no reduction in brain bleed size on cross-sectional imaging, suggesting an alternative mechanism may explain its effect. Plasmin activates complement proteins C3 and C5, and complement activation is linked to worse outcomes in animal TBI models.
View Article and Find Full Text PDFFlight-Crew Administration Speeds Time to Tranexamic Acid: FAST TXA Study.
Air Med J
August 2025
Department of Emergency Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA; Blizard Institute for Neuroscience, Surgery, & Trauma, Barts & The London School of Medicine, London, United Kingdom.
Objective: Tranexamic acid (TXA) is a standard therapy for the early treatment of life-threatening traumatic hemorrhage. Multiple studies suggest a benefit to earlier TXA, and meta-analysis calculates that each 15-minute time savings achieved by prehospital TXA improves mortality 10%. In trauma patients for whom helicopter emergency medical services (HEMS) initiated prehospital TXA, this study's primary aim was to calculate the minutes' time savings achieved compared with hypothetical TXA initiation at trauma centers.
View Article and Find Full Text PDFTranexamic Acid in Trauma.
Ann Emerg Med
September 2025
Department of Emergency Medicine, North Memorial Health Level I Trauma Center, Minneapolis, MN, National Association of EMS Physicians.
A Joint Position Statement and Resource Document of NAEMSP, ACEP, and ACS-COT Prehospital use of tranexamic acid (TXA) has grown substantially over the past decade despite contradictory evidence supporting its widespread use. Since the previous guidance document on the prehospital use of TXA for injured patients was published by the National Association of EMS Physicians, the American College of Surgeons Committee on Trauma, and the American College of Emergency Physicians in 2016, new research has investigated outcomes of patients who receive TXA in the prehospital setting. To provide updated evidence-based guidance on the use of intravenous TXA for injured patients in the emergency medical services (EMS) setting, we performed a structured literature review and developed the following recommendations supported by the evidence summarized in the accompanying resource document.
View Article and Find Full Text PDFTranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT.
J Trauma Acute Care Surg
September 2025
From the Department of Emergency Medicine (W.J.B.), and Department of Pharmacy Practice (K.A.K.), University of New Mexico Health Sciences Center, Albuquerque, New Mexico; Department of Emergency Medicine (R.E.O.), Montrose Regional Health, Montrose; Department of Surgery (E.M.C.), Denver Health Med
Prehospital use of tranexamic acid (TXA) has grown substantially over the past decade despite contradictory evidence supporting its widespread use. Since the previous guidance document on the prehospital use of TXA for injured patients was published by the National Association of EMS Physicians, the American College of Surgeons Committee on Trauma, and the American College of Emergency Physicians in 2016, new research has investigated outcomes of patients who receive TXA in the prehospital setting. To provide updated evidence-based guidance on the use of intravenous TXA for injured patients in the emergency medical services (EMS) setting, we performed a structured literature review and developed the following recommendations supported by the evidence summarized in the accompanying resource document.
View Article and Find Full Text PDF